Daiichi Sankyo and Lilly, in partnership with the World Heart Federation, developed this international survey. The survey was conducted by GfK Roper in Canada, France, Germany, Italy, Mexico and the UK among nationally representative samples of adults aged 40 and older who suffered from heart attack or other serious heart conditions, such as angina. A total of 3,011 patients were sampled [All Country Summary p29]. The survey was completed in December 2008. The sampling error, at the 95 percent confidence level, for results based on the total is +/- 3.4 percentage points. The sampling error is higher for analysis on subgroups.
About the World Heart Federation
The World Heart Federation, a non-governmental organization based in Geneva, Switzerland, is committed to helping the global population achieve a longer and better life through prevention and control of heart disease and stroke, with a particular focus on low and middle-income countries. It is comprised of 198 member societies of cardiology and heart foundations from 100 countries covering the regions of Asia-Pacific, Europe, the Americas and Africa. For further information visit: www.worldheart.org
About Daiichi Sankyo Company, Limited
A global pharmaceutical innovator, Daiichi Sankyo Co., Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. Areas of primary focus for Daiichi Sankyo research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit www.daiichisankyo.com.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, USA, Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.
O--LLY
(Logo: http://www.newscom.com/cgi-bin/prnh/20061120/DSLLOGO )
(Logo: http://www.newscom.com/cgi-bin/prnh/20090331/CL90914LOGO )
(Logo: http://www.newscom.com/cgi-bin/prnh/20090831/DE67926LOGO )
Charanjit Jagait of the World Heart Federation, +41-22-807-0334 (office); or Derin Denham of Eli Lilly and Company, +1-317-277-6749 (office), +1-317-370-1435 (mobile); or Kimberly Wix of Daiichi Sankyo (US), +1-973-695-8338 (office), +1-908-656-5447 (mobile); or Michaela Paudler-Debus of Daiichi Sankyo Europe, +49-(0)-89-7808-685 (office), +49-(0)-172-845-8974 (mobile). Logo: http://www.newscom.com/cgi-bin/prnh/20061120/DSLLOGO, http://www.newscom.com/cgi-bin/prnh/20090331/CL90914LOGO, http://www.newscom.com/cgi-bin/prnh/20090831/DE67926LOGO
